Nacogdoches: 936-569-8278
Jasper: 409-381-8100
Seeing Is Believing
  Home
Clinical Research
Protocol                     Study                                                                                                                
C-91-75   Comparison of Rimexolone 1% ophthalmic suspension to placebo in control of post cataract inflammation. Alcon, 1992.
C-95-07   Alcon, February 1996 – March 1999.
125   Pharmos Corp, May 1996 – November 1996.
C-96-42   Clinical Study of an Intraocular Lens. Alcon, September 1997- March 1999.
C-97-75   Safety and efficacy of AL-3789 2% ophthalmic suspension versus placebo in primary pterygium patients. Alcon, October 1997 – February 2000.
C-97-54   Open-Label efficacy and safety study of 2% AL-3789 ophthalmic suspension in patients with recurrent pterygium. Alcon,October 1997 – February 2000.
C-97-65   A study to assess methods of evaluating product characteristics of ophthalmic suspensions in the eye employing VEXOL 1.0% ophthalmic suspension compared to Rimexolone 1.0% ophthalmic suspension (process A and C) in post-cataract surgery patients. Alcon, January 1998 – May 1998.
C-97-53   Efficacy and safety of AL-3789 ophthalmic suspension (2%, 1%, 0.1%) versus placebo in the prevention of neovascularization following recurrent pterygium excision. Alcon, January 1998 – February 2000.
C-98-41   An evaluation of the anti-inflammatory efficacy of a modified formulation of Rimexolone 1.0% ophthalmic suspension compared to VEXOL 1.0% ophthalmic suspension in post-cataract surgery patients. Alcon, January 1999 – May 1999.
C-00-02   Safety and efficacy of Moxifloxacin ophthalmic solution versus Moxifloxacin vehicle in the treatment of bacterial conjunctivitis using bid dosing. Alcon, May 2000 – February 2001.
C-00-37   Investigation of positional stability of the ACRYSOF single piece intraocular lens. Alcon, November 2000 – January 2003.
C-01-63   Clinical study of ACRYSOF multifocal intraocular lens. Alcon, December 2001 – August 2004.
C-02-39   A multi-center, randomized, paralled group study to evaluate the safety and the performance of Viscous intraocular irrigating solution during cataract extraction and IOL implantation surgery. Alcon, November 2002 – November 2003.
C-00-14   Clinical study of Acrysof Blue Blocker intraocular lens. Alcon, November 2002 – May 2003.
C-02-59   Alcon, December 2002 – January 2003.
5383   Clinical study of acrylic intraocular lens. AVS, April 2003 – September 2009.
C-03-18   A controlled, randomized, multi-center, observer-masked study of the safety and efficacy of next generation ophthalmic viscosurgical device during cataract extraction and IOL implantation surgery. Alcon, May 2003 – November 2003.
C-02-23   US clinical study of the ACRYSOF angle-supported phakic intraocular lens. Alcon, July 2003.
C-03-33   A multi-centered, double-masked, randomized, parallel group study to evaluate the safety and the performance of StablEyz intraocular irrigating solution during cataract extraction and IOL implantation surgery.  Alcon, August 2003 – March 2004.
C-03-32   Preoperative and postoperative use of Nepafenac ophthalmic suspension, 0.1% for the treatment of ocular inflammation associated with cataract surgery. Alcon,  January 2004 – May 2004.
C-03-07   Clinical evaluation of AquaLase liquefaction using saline liquefaction solution (0.9% NaCl). Alcon, 2004.
C-03-37   Alcon, July 2004 – October  2004.
C-04-28   Post-Market evaluation of the ACRYSOF natural IOL model SN60WF. Alcon, October 2004 – August 2005.
19-002   A prospective, randomized, parallel-group, multi-center, observer-masked trail comparing the efficacy and safety of 0.5% levofloxacin with 1.0% prednisolone acetate to 0.5% levofloxacin monotherapy, 1.0% prednisolone acetate monotherapy and vehicle for the treatment of peripheral inflammatory keratitis. Santen, June 2005 – March 2006.
C-03-35   Post-market study of the ACRYSERT model SA60AS delivery system. Alcon, 2005.
C-04-41   Nepafenac. Alcon, July 2005 – June 2006.
C-05-43   A single-masked, multi-center, pharmacokinetic pilot study of Tobradex AF suspension formulations. Alcon, September 2005 – January 2006.
C-05-19   An open-label, single-dose, pharmacokinetic study of Nepafenac and Amfenac, or Ketorolac, in human aqueous humor following administration of Nevanac or Acular LS, respectively. Alcon, September 2005 – December 2005.
C-05-20   Nevanac. Alcon, April 2006 – December 2006.
C-05-23   A double-masked, parallel-group, randomized, single-dose bioequivalence study of Tobradex AF suspension and Tobradex ophthalmic suspension. Alcon, June 2006 – November 2006.
CMS-06-05   A multi-center, randomized, double-masked, single-dose, pharmacokinetic clinical study of Nepafenac and Amfenac, or Ketorolac, or Bromfenac in human aqueous humor following administration of Nevanac, Acular LS, or Xibrom, respectively. Alcon, July 2006 – December 2006.
C-05-31   A randomized, double-masked safety and efficacy study of FID# 109980 compared to FID# 110656 in the treatment of dry eye. Alcon, August 2006 – August  2007.
C-05-57   Phase 3 US clinical study of the ACRYSOF angle-supported phakic IOL. Alcon  August  2006 – January 2011.
BRSC02   Xibrom. Ista, October 2006.
C-06-37   Tobradex AF. Alcon, January  2007 – May 2007.
C-06-40   Restor +3.0 Add. Alcon, June 2007 – April  2008.
CL S&E 0802071-P   Xibrom clinical evaluation. Ista, October  2007 – May  2008
CL S&E 0415081-P   Efficacy and safety of Xibrom 0.09% QD vs. placebo QD for treatment of ocular inflammation and pain associated with cataract surgery. Ista, June 2008 – February 2009.
CL-PKT-0415083-P   A multi-center, randomized, double-masked, bioequivalence study of T-Pred (prednisolone acetate 1% and trobramycin 0.3% ophthalmic suspension) compared to Pred Forte (prednisolone acetate) 1% sterile ophthalmic suspension. Ista, August 2008 – August  2009.
C-07-53   An evaluation of the efficacy and safety of AL-46383A ophthalmic solution for the treatment of adenoviral conjunctivitis. Alcon, June 2009 – November  2010.
C-08-077   A randomized, double-masked study of AL-38583 0.05% ophthalmic solution and AL-38583 0.10% ophthalmic solution versus AL-38583 vehicle in the treatment of dry eye. Alcon, July  2009 – February  2010.
C-07-43   A clinical safety and efficacy comparison of Nevanac 0.1% to vehicle following cataract surgery in diabetic retinopathy patients. Alcon, July 2009  – September  2010.
C-08-062   Clinical investigation of extended cylinder power ACRYSOF toric IOLs.   Alcon, July  2009 – June 2010.
588   A randomized, multicenter, double-masked, parallel-group dose ranging clinical safety and efficacy evaluation of BOL-303242-X ophthalmic suspension versus vehicle for the treatment of inflammation following cataract surgery. Bausch & Lomb,  August  2009 – June 2010.
C-07-45   Clinical study of the ACRYSOF II Natural IQ IOL. Alcon, November 2009 – January 2011.
GC-006   A prospective, randomized, controlled, parallel groups, multicenter clinical investigation of the Glaukos Trabecular Micro-Bypass Stent model GTS400 in conjunction with cataract surgery. Glaukos, January  2010 – August  2010.
C-09-057   Assessment of properties of IOL materials. Alcon, May 2010 – January 2011.
C-09-054   Assessment of ACRYSOF II Natural IQ IOL model SY60WF properties.  Alcon, July  2010 – December  2010.
C-09-055   Clinical evaluation of Nepafenac ophthalmic suspension, 0.3% for prevention and treatment of ocular inflammation and pain after cataract surgery. Alcon,  July 2010 – July 2011.
658   A prospective multicenter clinical study to evaluate the safety and effectiveness of a Bausch & Lomb one-piece hydrophobic acrylic intraocular lens in subjects undergoing cataract extraction. Bausch & Lomb, September  2010 – August 2011.
C09—001   A study of phenylephrine HCI’s and Ketorolac Tromethamine’s ability, alone and in combination, to maintain mydrisasis and relieve pain and inflammation in subjects undergoing unilateral cataract extraction with lens replacement (CELR). Omeros, November 2010 – March 2011.
C-11-003   Clinical Evaluation of Nepafenac Ophthalmic suspension, 0.3% compared to Nepafenac ophthalmic suspension 0.1% and vehicle for prevention and treatment of ocular inflammation and pain associated with cataract surgery. Alcon, March 2011 – November 2011.
C-09-036   Clinical Investigation of Acrysof IQ restor multifocal toric intraocular lens models SND1T3/SND1T4/SND1T5/SND1T6. Alcon, July 2011 – February 2013.
C-09-076   Clinical Investigation of AcrySof IQ Monofocal Toric Intraocular Lens Model SN6AT2. Alcon, February 2012 – February 2013.

 



Nacogdoches
5300 North Street
Nacogdoches, TX 75965
Phone: 936-569-8278
Fax: 936-569-0275
1-800-753-3846

Jasper
103 West Gibson Street
Jasper, TX 75951
Phone: 409-381-8100
Fax: 409-381-8101


Join Our Team

Patient Portal
Privacy Policy
Site Map

© 2016 Lehmann Eye Center, All Rights Reserved